Electromed (NYSE:ELMD) Downgraded by StockNews.com

Electromed (NYSE:ELMD) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

Separately, TheStreet raised shares of Electromed from a “c+” rating to a “b-” rating in a research report on Wednesday, February 21st.

Electromed Stock Down 4.4 %

ELMD opened at $15.99 on Friday. Electromed has a 52-week low of $8.80 and a 52-week high of $17.85. The company has a 50 day moving average of $15.64 and a two-hundred day moving average of $12.26. The company has a market cap of $137.67 million, a P/E ratio of 35.53 and a beta of 0.43.

Electromed (NYSE:ELMD) last posted its earnings results on Tuesday, February 13th. The company reported $0.19 EPS for the quarter. Electromed had a net margin of 7.62% and a return on equity of 10.32%. The business had revenue of $13.69 million for the quarter.

Institutional Trading of Electromed

An institutional investor recently raised its position in Electromed stock. Punch & Associates Investment Management Inc. grew its holdings in shares of Electromed, Inc. (NYSE:ELMD) by 0.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 418,896 shares of the company’s stock after purchasing an additional 1,431 shares during the period. Punch & Associates Investment Management Inc. owned 4.89% of Electromed worth $4,352,000 as of its most recent SEC filing. Institutional investors and hedge funds own 40.82% of the company’s stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function.